Article Details
Retrieved on: 2025-05-23 20:08:21
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin treatments, has granted 102,880 restricted ...
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here